Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: A rare entity

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1839-1841

  Ohanian, Maro ^a   Leventaki, Vasiliki ^a   Verstovsek, Srdan ^a   Estrov, Zeev ^a   Lin, Pei ^a   Yin, Cameron ^a   Kantarjian, Hagop ^a   Huh, Yang ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL DISCOMFORT; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CASE REPORT; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; EXON; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INSOMNIA; IRON BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTOSIS; MALE; MEGAKARYOCYTE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; PHLEBOTOMY; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SKIN TUMOR; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; URIC ACID BLOOD LEVEL;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRIMARY MYELOFIBROSIS;

EID: 84865033356     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.663916     Document Type: Letter

References (14)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classifi cation of tumours of haematopoietic and lymphoid tissues.Lyon: IARC; 2008.
2. Teff eri A. How I treat myelofi brosis. Blood 2011;117:3494-3504.
3. Beer PA, Jones AV, Bench AJ, et a l. Clonal diversity in the myeloproliferative neoplasms: Independent origins of genetically distinct clones. Br J Haematol 2009;144:904-908.
4. Lambert JR, Everington T, Linch DC, et al. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: A new disease paradigm. Blood 2009;114:3018-3023.
5. P olliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofi brosis and myeloid metaplasia. Am J Hematol 1980;9:211-220.
6. C amos M, Cervantes F, Montoto S, et al. Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma 1999;32:395-398.
7. Teff eri A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550-566.
8. Ma W, Zhang X, Wang X, et al. MPL mutation profi le in JAK2 mutation-negative patients wiThmyeloproliferative disorders. Diagn Mol Pathol 2011;20:34-39.
9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468.
10. Bercovich D, Ganmore I, Scott LM, et a l. Mutations of JAK2 in acute lymphoblastic leukaemias associated wiThDown's syndrome. Lancet 2008;372:1484-1492.
11. Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723-1735.
12. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891-2900.
13. N akao M, Janssen JW, Seriu T, et al. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using lightcycler technology. Leukemia 2000;14:312-315.
14. Estrov Z. Stem cells and somatic cells: Reprogramming and plasticity. Clin Lymphoma Myeloma Leuk 2009;9(Suppl. 3): S319-S328.